Market capitalization | $38.18m |
Enterprise Value | $10.42m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.44 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-21.20m |
Free Cash Flow (TTM) Free Cash Flow | $-17.24m |
Cash position | $28.05m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Lantern Pharma Inc:
1 Analyst has issued a forecast Lantern Pharma Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.18 -0.18 |
6%
6%
|
|
EBITDA | -21 -21 |
26%
26%
|
EBIT (Operating Income) EBIT | -21 -21 |
26%
26%
|
Net Profit | -19 -19 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on leveraging artificial intelligence (A.I.), machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, a non-hormone, non-chemotherapy, next generation alkylating agent with nanomolar potency that damages DNA in cancer cells that overexpress certain biomarkers indicated primarily in solid tumors, such as those in prostate and ovarian cancers. The company was incorporated in 2013 and is based in Dallas, Texas.
Head office | United States |
CEO | Panna Sharma |
Employees | 21 |
Founded | 2013 |
Website | www.lanternpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.